Else Kröner Forschungskolleg Cologne

Modern-day cancer therapy is witnessing a paradigmatic shift, away from globally toxic chemo- and radiotherapy, towards the use of non-genotoxic targeted small molecules and antibodies. These efforts are rooted in a steadily deepening molecular understanding of the patho-mechanisms underlying malignant transformation. The advent of modern technologies, particularly genome sequencing and novel approaches in high-performance computational biology, has revolutionized cancer research. These knowledge gains led to the development and clinical implementation of numerous novel drugs that specifically target genotype-stratified tumor entities. Prime examples are the use of specific tyrosine kinase inhibitors for EGFR-mutant-, EML4-ALK-rearranged- or ROS1-rearranged tumors, as well as BCR-ABL-fused leukemia.

These groundbreaking developments necessitate a profound change in the training and education of young oncologists. These physicians need solid clinical skills and a thorough training in molecular cancer research. Thus, we carefully assembled a peerless consortium of clinical opinion leaders and internationally competitive cancer researchers to create a structured training program for physician scientists that aim for a career in translational oncology.

Our consortium is tailored to address the question of clonal evolution and selection in response to targeted therapy. We consider this overarching question to be the major challenge in modern-day cancer therapy, as the majority of targeted approaches are eventually limited by the occurrence of acquired drug resistance. Our proposal is a cross-faculty joint effort of the members of the Center for Cancer and Immunology Research at the comprehensive cancer center of the University Cologne (CIO-CCIR) and also involves a non-university research center (Max-Planck-Institute for Metabolism Research). 


Ron Jachimowicz´s paper on UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors is published

The Else Kröner Forschungskolleg Cologne fellow Ron Jachimowicz has published his paper in Cell.

Prof. Matthias Fischer publishes his work on the mechanistic classification of clinical phenotypes in neuroblastoma

Principal Investigator at the Else Kröner Forschungskolleg Cologne publishes in Sciene. The EKF fellow, Carolina Rosswog, has contributed to this...

Else Kröner Forschungskolleg Cologne 1st Annual Retreat

Annual Retreat on 19th of October 2018

Adalbert-Czerny-Prize for Prof. Fischer

Children's oncologist awarded by specialist society

PD Dr. Dr. Roland Ullrich publishes his work on synergistic anti-angiogenic treatment effects on breast cancer

PD Dr. med. Dr. nat. med. Roland Ullrich

The Else Kröner Forschungskolleg Cologne principal investigator PD Dr. Roland Ullrich and his team have published their work on Synergistic...

ERC Advanced Grant for Professor Manolis Pasparakis

Scientist from Cologne wins the most important European Research grant for the second time

Martin Peifer publishes his work on clonal dynamics in cancer under therapeutic pressure

The Else Kröner Forschungskolleg Cologne principal investigator Martin Peifer and his team have published their work on clonal dynamics in cancer...

Manolis Pasparakis publishes his work on the role of RIPK1 in liver carcinogenesis

EKFS Cologne Manolis Pasparakis

The Else Kröner Forschungskolleg Cologne principal investigator Manolis Pasparakis and his team published their work on RIPK1 and its role in liver...

The Else Kröner Forschungskolleg Cologne has been successfully established in March 2017

Else Kröner Forschungskolleg established

The Else Kröner Forschungskolleg Cologne has received funding for the establishment of an innovative, personalized training program for young...


Seminar: Single cell genomics, January 17th 2019

Talk with Dennis Eastburn, San Francisco, CA

20th International AEK Cancer Congress, Feburary 27th - March 1st 2019

Translating Cancer Biology: From Basic Mechanism to Therapeutic Exploitation

1st German Cancer Research Congress, February 4th–5th 2019

Scientific program and presentation of innovative research results

International Symposium on Hodgkin Lymphoma, October 27.-29., 2018

ISHL Cologne

Most recent advances in basic research, diagnosis and treatment of Hodgkin Lymphoma

Annual Retreat, October 19th, 2018

Annual Retreat

First EKF-Cologne Annual Retreat

Frontiers in Cancer Research, October 9.-11. 2018

Frontiers in Cancer Research

In October, the German Cancer Research Center (DKFZ) will hold the Frontiers in Cancer Research Conference

Frankfurt Cancer Conference, September 25.-27., 2018

Frankfurt Tumor Conference

Turning moleular information into novel cancer therapies

XI. International Workshop of DCLLSG, September 21.-22. 2018

In September, the German CLL Study Group will hold an international Workshop

Cologne Cancer Club, July 11th, 2018

Cologne Cancer Club

Circulating tumor DNA in B-cell malignancies

11th Missing Link in Translational Science Seminar, June 17th, 2018

“Translating discoveries in lymphoma biology into the clinic”

Cologne Cancer Club, April 24th, 2018

Cologne Cancer Club

Using biomarkers to guide antiangiogenic

59th ASH Annual Meeting, December 09.-12., 2017, Atlanta, GA, USA

ASH Annual Meeting

In December, the American Association of Hematology holds its annual meeting. Many of our principle investigators will attend this conference and...

EKFS Cancer Symposium 2017, Exploiting Tumor-Specific Vulnerabilities for Improved Cancer Treatment, to be held in Göttingen, Nov. 15.-17. 2017

In November, the Else Kröner Forschungskolleg Göttingen will hold their 2017 Symposium on targeting tumor-specific vulnerabilities. Christian...